Easy (targeted) approaches rely on predefined panels or primer sets to enrich known regions of interest. They offer fast turnaround, simplified data analysis, and lower cost per sample—ideal for clinical routine and monitoring known variants.
De novo (discovery) approaches require no prior knowledge of the genome. Whole-genome or whole-transcriptome sequencing captures all variation, enabling the discovery of novel fusions, structural variants, and unknown pathogens. This approach demands more complex bioinformatics but unlocks the full landscape of molecular alteration.
Our hybrid technology bridges both worlds: a rapid enrichment workflow (1 hour hands-on, 4 hours total) that preserves multi-omic signatures while delivering discovery-grade coverage and sensitivity down to 0.001% VAF.
- Targeted panels for routine clinical monitoring
- Whole-genome de novo discovery for novel biomarker identification
- Unified bioinformatics pipeline supporting both modes
